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It  is  known  that  mice  bearing  plasmacytomas  have  an  impaired  immune 
response to both thymus-dependent (TD) ~  and thymus-independent (TI) antigens 
(1-4).  This effect is to a  large extent unrelated to paraprotein production (5) 
and is greatest on the primary response, although decreases in  the secondary 
response are frequent (1). 
Recently two  IgD-producing plasmacytomas, called TEPC-1017  and -1033, 
have been described (6), but no reports on their ability to affect immune responses 
have appeared. In view of the presence of IgD on the surface of the majority of 
B cells, in spite of its extremely low representation in serum, many hypotheses 
about the role of IgD as a differentiation (7, 8) or proliferation (9) trigger of B 
cells have been put forth. The presence of IgD on B cells during TD immune 
responses in vitro appears to be particularly important (10). 
On the other hand, subpopulations of T  cells are known to have receptors for 
Fc portions of a variety of Ig classes, including IgM (11), IgG (12), IgA (13), and 
IgE (14). Such cells have been shown to modulate immune responses both upward 
and downward (15-17). No T  cell populations with receptors for IgD have been 
described.  If such cells exist and can modulate the immune response,  then it 
might be expected that IgD-secreting plasmacytomas would indirectly influence 
immune responses, since they would cause a marked change in serum IgD levels. 
In the present study, we show that TD immune responses of TEPC-1017- and 
TEPC-1033-bearing  mice are greatly enhanced and that treatment with  IgD- 
containing ascites fluid can mimic this effect of IgD-secreting plasmacytomas on 
the host. 
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Materials and  Methods 
Mice.  BALB/c mice were obtained from Charles River Breeding Laboratories, Inc., 
Wilmington,  MA.  Athymic  BALB/c  mice  were  supplied  by  the  Division  of  Cancer 
Treatment Animal Program, National Cancer Institute, Bethesda, MD. 
Antigens and Adjuvants.  Sheep erythrocytes (SE) were purchased from Colorado Serum 
Co., Denver CO; keyhole limpet hemocyanin (KLH) from Schwarz/Mann  Div., Becton, 
Dickinson & Co., Orangeburg, NY; Ficoll, 40,000 mol wt, from Pharmacia Fine Chemicals, 
Piscataway,NJ; and trinitrophenyl sulfonic acid from Sigma Chemical Co., St.  Louis, MO. 
Brucella abortus (BA) was provided by the U. S.  Department of Agriculture,  Ames, IA. 
Trinitrophenyl (TNP) and dinitrophenyl (DNP) conjugates were prepared as described 
by Little and Eisen (18),  except for TNP-Ficoll,  which was prepared according to the 
method  of Mishell  and  Dutton  (19).  Bordetella  pertussis  (Massachusetts  Public  Health 
Biology  Laboratories) and  Escherichia coil endotoxin  (lipopolysaccharide  [LPS])  (Difco 
Laboratories, Detroit, MI) were used as adjuvants in some experiments. 
Immunization.  Mice were injected intravenously at 6-8 wk of age (day 0) with either 
10 ug TNP-Ficoll,  100 #g TNP-KLH,  i00 ttg DNP-ovalbumin (DNP-OVA), or 80 ~g 
TNP-BA. Primary responses to TNP-Ficoll and TNP-BA were determined on day 4, and 
to TNP-KLH and DNP-OVA on day 5 or 7 after immunization. For secondary responses, 
mice injected with TNP-BA and TNP-KLH were boosted 14 d later, and their responses 
were determined 5 d after boosting. Some mice received  10 t~g TNP-KLH in the front 
footpads. 
Plasmacvtomas.  Plasmacytomas were serially transplanted by intraperitoneal  injection 
of 106 cells in BALB/c mice. Ascites cells and fluids were collected 2 wk after inoculation 
of tumor cells. Subcutaneously growing tumors were obtained by the injection of minced 
tumor pieces. To study the effect of these tumors on the immune response, we injected 
mice bearing subcutaneous tumors with a primary dose of antigen  2-3 wk after tumor 
injection.  Serum  and  ascites  fluid  were  examined for the  presence of IgD by double 
diffusion in agar (20) using goat anti-mouse 6 prepared by immunization of a goat with 
myeloma protein  from  TEPC-1033.  The  antiserum  was  absorbed  in  sequence  with 
Sepharose 4B coupled to mouse lg, MOPC-104E (u, ~,), UPC-10 (3'2a, ~) and Y 5606 (3,3, 
~).  The absorbed  antiserum  no  longer  reacted  with  normal  mouse  serum.  The  IgG 
fraction of this antiserum, prepared by chromatography on DEAE cellulose, was conju, 
gated to fluorescein or rhodamine and used to stain viable mouse spleen and lymph node 
cells for surface IgD. Double staining with goat anti-mouse Fab conjugated to a different 
fluorochrome than that used for the anti-IgD was used to determine the percentage of 
IgD-bearing B cells. Surface staining was examined as described previously (21). 
Purification  oflgD.  TEPC-1017  ascites was passed over a  2-g column  of goat anti- 
mouse IgD-coupled Sepharose 4B (Pharmacia Fine Chemicals). After extensive washing 
with  phosphate-buffered saline,  the  IgD bound  to  the  column  was eluted  with  4.0  M 
MgCI.2. This eluate was dialyzed and reconstituted  to the same volume as the original 
ascites fluid.  It formed a precipitin band with anti-mouse lgD upon double diffusion in 
agar. 
Plaque-forming Cell (PFC) Assay.  Anti-SE and anti-TNP-PFC were assayed by the slide 
modification  of the  technique  of Jerne  et  al.  (22).  TNP-SE  were  prepared  using  the 
method described by Rittenberg and Pratt (23).  IgG-producing cells were developed with 
rabbit anti-mouse Ig in the complement and goat anti-tL in the agar (24). 
Results 
The plasmacytomas became palpable  10-14 d  after subcutaneous injection  in 
~90% of injected mice. No IgD could be detected by double diffusion in agar in 
serum from normal mice. IgD became detectable in the serum of tumor-bearing 
mice in ~2 wk and remained high until the mice became moribund 6-8 wk after 
tumor injection. Sera taken ~4 wk after the injection of tumor reacted at dilutions 
ranging from 1:16 to  1:32.  In mice that received  10 ~ tumor cells i.p., the ascites XUE  ET  AL.  105 
fluid collected  10-14  d  later contained sufficient IgD  to be  detectable up  to 
dilutions of 1:32.  After -5-6  wk,  small tumor nodules could be  seen  in  the 
spleen. Mice showing such evidence of splenic plasmacytoma growth were not 
used for the analysis of PFC: Expressed as the percentage of body weight, spleens 
from tumor-bearing mice were approximately twice as large as spleens in control 
mice. The percentages of B cells showing membrane IgD were similar in spleen 
and lymph node cell suspensions from IgD myeloma-bearing and control mice. 
The values in all cases fell between 80 and 95%. 
The  effects of TEPC-1017  and  -1033  on  the splenic  PFC  responses  after 
primary or secondary intravenous injections of TNP-KLH are presented in Fig. 
1. Both tumors enhanced the primary 19S and 7S responses three to fourfold, 
whereas the secondary response induced 2 wk after priming was enhanced three 
to fourfold by TEPC-1033 and as much as four to fivefold by TEPC-1017. The 
primary  response  to  10  #g  TNP-KLH  injected  into  the  front  footpad  was 
measured in the draining brachiai lymph node. These responses were very low 
in control mice (110  PFC/node), but again increased fourfold in TEPC-1017- 
bearing mice (data not shown).  Secondary responses  induced in  the  draining 
lymph node after a  14-d interval were also threefold enhanced for both 19S and 
7S PFC in the TEPC-I 017-bearing mice. Some mice, which had been injected 
with minced tumor but  failed to develop palpable  tumors,  were also injected 
with  TNP-KLH  3  wk  later.  Primary responses  in  these  mice  were  three  to 
fourfold higher than in control mice (data not shown). It is likely that in these 
mice there was production of IgD,  but not to a  level detectable in serum by 
immunoprecipitation; the  serum  IgD  levels might have been  similar to  those 
obtained in mice injected with IgD-containing ascites (see below). We also studied 
a few mice that had failed to grow palpable tumors after subcutaneous injection 
with 104-10  6  dissociated plasmacytoma cells.  These mice showed only approxi- 
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FIGURE  l.  Responses  of lgD-secreting, myeloma-bearing  mice  to TNP-KLH.  PFC per spleen 
responses determined  on day 5 after a primary intravenous  injection  of 100 #g TN P-KLH or 
after a secondary intravenous injection 2 wk later. Responses of tumor-bearing mice are 
expressed as percentage of control responses, for TEPC-I  017 (striped bars) and TEPC-1033 
(solid bars), n = 10, 11, and 7 for primary  response; 100% values  for PFC/spleen  were 19,000 
(19S) and 7,400 (7S). i1 = 4, 4, and 3 for secondary  response; 100% values were 25,100 (19S) 
and 57,200 (7S) in one experiment  and 3,500 and 15.500 PFC/spleen in the other. 106  ENHANCEMENT  OF  ANTIBODY  PRODUCTION  BY  lgD 
mately twice higher 19S and a slightly increased 7S primary response as compared 
with control mice, upon immunization  4 wk after tumor cell injection. 
The primary  19S and 7S responses of mice injected with 800 ~g TNP-BA i.v. 
2 wk after receiving transplants  of either TEPC-1017 or -1033 were depressed 
to ~50%  of the control levels (data not shown).  Primary  19S and  7S responses 
to 80 #g TN P-BA were enhanced two to threefold in TEPC-1017-bearing mice, 
but were depressed  by TEPC-1033  (Fig.  2).  In  contrast,  both  tumors  greatly 
enhanced  secondary responses to  TNP-BA:  three  to fourfold for TEPC-1033 
and four to sevenfold for TEPC-1017. Since preparation for a secondary response 
is much  more T  dependent  than  the primary  response (25),  these results sug- 
gested that the IgD-producing  plasmacytomas caused a  preferential  increase in 
TD responses. 
Fig.  3 shows the responses of TEPC-1017- and -1033-bearing mice to TNP- 
Ficoll. It was again noted that TEPC-1017 enhanced both 19S and 7S responses 
by a  factor of 1.5-2 whereas TEPC-1033  only enhanced the 7S response.  The 
effect on responses to two different TNP-Ficoll preparations was comparable. 
We compared the effect of TEPC-1017 with that of other agents that enhance 
immune  responses.  The  results  in  Table  I  show that  the primary  response  to 
intravenously injected DNP-OVA was enhanced to approximately the same level 
in  TEPC-1017-bearing  mice  as  it  was  in  normal  mice  given  109  B.  pertussis 
organisms intravenously,  simultaneously with the antigen.  Responses in TEPC- 
1017-bearing mice to DN P-OVA and B. pertussis were not significantly enhanced 
over those in  control  mice  injected  with  antigen  and B.  pertussis.  The  data  in 
Table II show that the secondary response to intravenously injected DNP-OVA 
was extremely low and  lacked a  significant  7S component.  Although  the  19S 
PFC  were  again  higher  in  TEPC-1017-bearing  mice,  the  7S  PFC  response 
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FIGURE 2.  Responses of lgD-secreting, myeloma-bearing mice to TNP-BA. PFC per spleen 
responses determined 4 d after intravenous injection of 80 #g TNP-BA, presented as in Fig. 
1. n =  4, 3, and 3 for primary response; 100% values for PFC/spleen were 100,000 (10S) and 
41,700 (7S).  n  =  9,  5,  and 3  for secondary response;  100%  values were  26,300  (19S) and 
57,400 (7S) PFC/spleen. XUE  ET  AL.  107 
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FIGURE 3.  Primary  responses  of  IgD-secreting,  myeloma-bearing  mice  to  two  different 
preparations  of  TNP-FicolI.  PFC  per  spleen  were  determined  on  day  4  after  intravenous 
injection  of 10 ~g TNP-Fico]I,  presented as in Fig.  1. (Prep. A) n -- 7, 9, and 4; 100% values 
for PFe/spleen  were 338,800 (19S) and 180,800 (7S). (Prep. B) n -- 8, 8, and 5; 100% values 
for PFC/spleen  were 240,500 095) and 23,000 (7S). 
TABLE I 
Effect of TEPC-1017 on the Primary Immune Response to DNP-OVA 
With and Without B. pertussis 
B. pertussis  TEPC-1017  Days after 
injected  bearing  antigen 
day 0 
Geometric mean PFC/spleen 
X  SE (n)*  -.i- 
19S  7S 
-  -  5 
-  +  5 
+  -  5 
+  +  5 
+  -  7 
+  +  7 
800  X  1.1 
5,000  x  1.7 
6,200  .x  1.2 
8,800  _x  1.5 
4,400  x  1.2 
7,900  .x  1.0 
1,000  _.x  1.1  (2) 
2,000  x  1.4 (3) 
1,300  x  1.3 (9) 
2,000  x  1.2 (3) 
835  X+  1.4 (5) 
1,600  +X  1.2 (3) 
* PFC/spleen determined  on day 5. 
remained insignificant. Mice injected with DNP-OVA plus adjuvants, in contrast, 
had  excellent  19S  and  7S  responses,  which  were  further  enhanced  by  the 
presence  of growing  TEPC-1017.  The  degree  of enhancement  caused  by  the 
IgD-secreting plasmacytoma was much greater in the mice immunized with DNP- 
OVA and LPS than in the mice receiving DNP-OVA and B. pertussis. 
The effect of growing IgD-secreting tumors could be reproduced by pretreat- 
ment  of the  mice  with  four injections  of  1  ml  of IgD-containing  ascites  fluid 
(Table  III).  The amount  of IgD injected was not sufficient to yield  detectable 
serum  IgD  in  the  recipient  mice  20  h  after  a  single  injection  or  1  wk  after 
multiple injections of ascites fluid. The control responses to TNP-KLH in these 108  ENHANCEMENT  OF  ANTIBODY  PRODUCTION  BY  IgD 
TABLE  II 
Effect of TEPC-1017 on the Secondary Immune Response to DNP-OVA With and 
Without Adjuvants 
Geometric mean PFC/spleen  × 
TEPC-1017 
Response to:*  bearing*  SE (n)  i 
19S  7S 
DNP-OVA +  LPS 
Percent of control 
DNP-OVA + B. pertussis 
Percent of control 
DNP-OVA alone 
Percent of control 
×  1.3  (3)  -  36,600  +  ×  1.3  53,600  + 
x  1.2  (3)  +  161,900  +  ×  1.3  325,700  + 
+ 
442%  658% 
50,500  •  1.3  99,200  ~  1.1  (3) 
72,400  x_:  1.2  223,900  x  1.1  (2) 
143%  226% 
2,900  +x  1.3  500  .x  1.7 (6) 
6,100 x_. 1.1  300 +x  1.3 (6) 
207%  56% 
* Interval between primary and secondary intravenous injections of 100 ug DNP-OVA 
was  10 d. 
* Primary injection was given 2 wk after injection of TEPC-1017 subcutaneously. 
PFC per spleen determined 4 d after secondary injection. 
experiments are somewhat higher than in the experiments represented in Fig.  1 
because a different preparation of TNP-KLH was used. However, the magnitude 
of the 19S and 7S responses was increased three to fivefold by pretreatment with 
ascites fluid  1 wk  before antigen,  while  injection  of ascites  fluid  starting  1 d 
before antigen caused enhancement primarily of the 7S response (Exp.  1, Table 
III).  Ascites fluid prepared  with a  non-IgD-producing  plasmacytoma  (MOPC- 
321 G41, a kappa chain producer) decreased rather than increased the primary 
response to TNP-KLH. Furthermore, the results in Fig. 4 show that a comparable 
enhancing  effect on the primary  IgM  response to TNP-KLH is obtained with 
two  different  IgD-containing  myeloma  ascites  fluids  as  well  as  with  the  IgD 
isolated from one of them. 
To determine whether the effect of IgD was dependent upon the presence of 
T  cells, experiments on the primary response were repeated with nude (athymic) 
mice. The results of such an experiment are included in Table III (Exp. 3). They 
show that pretreatment with ascites, according to the same schedule that caused 
enhanced  responses in normal  mice, failed to increase the response of athymic 
mice. 
Discussion 
The present results clearly demonstrate that IgD-secreting myelomas enhance 
both  19S and  7S antibody responses of the host.  This  is an  effect opposite to 
that described for plasmacytomas that either do not secrete any Ig or secrete an XUE  ET  AL.  109 
TABLE  III 
Effect of IgD-containing Ascites Fluid on Primary Immune Response to TNP-KLH 
Geometric mean PFC/spleen 
Ascites fluid*  Time of injections*  SE (n)  0  Exp.  Mice  injected 
19S  7S 
1  BALB/c  None 
TEPC- 1017  -8, -7, -6, -5 
TEPC-1017  -1, 0, +1, +2 
2  BALB/c  None 
TEPC-1017  -8, -7, -6, -5 
MOPC 321G41  -8, -7, -6, -5 
3  Athymic  None 
BALB/c  TEPC-1017  -8, -7, -6, -5 
16,800  X__. 1.4 
51,900  .x  1.2 
20,800  x_.  1.1 
23,400 •  x  1.1 
86,100  _.x  1.1 
14,600  x_.  1.1 
3,500  .x  1.3 
3,700  x.  1.2 
22,400  .x  1.4 (4) 
97,200  .x  1.1 (4) 
84,600  x_.  1.2 (4) 
26,700  x.  1.2 (10) 
98,500  x.  1.7 (3) 
14,700  x.  1.I (4) 
<100 (5) 
<100 (4) 
* Ascites fluid collected 10-14 d after injection of 108 tumor cells intraperitoneally. 
* Time of injection is indicated in days, taking day 0 as the day of intravenous injection of 100 t~g 
TNP-KLH. Mice received four injections of 1 ml; the first and third were part intravenous and 
part intraperitoneal and the second and fourth were intraperitoneal only. 
! PFC/spleen determined on day +5. Anti-# added to agar for determination of 7S PFC. 
Ig other than IgD (1-5). Since pretreatment with ascites fluid from IgD-secreting 
myeloma-bearing  mice,  and  with  isolated  IgD from such a  fluid, also causes a 
marked enhancement of the PFC response to TNP-KLH, this effect appears to 
be mediated by IgD itself rather than by some other unidentified product of the 
myeloma cells. It should be noted that, in spite of considerable variability in the 
magnitude of the responses detected in untreated mice, probably due to the use 
of different antigen batches, the enhancing effect of IgD on the primary response 
was reasonably consistent. 
The mechanism by which IgD enhances immune responses does not appear to 
be via a direct effect on B cells. In the first place, the percentage of IgD  + B cells 
does not change  after  pretreatment  with  IgD.  Secondly,  treatment  with  IgD- 
containing ascites  1 wk before antigen  injection causes a  greater enhancement 
of the PFC response to TNP-KLH than does simultaneous administration  of the 
ascites fluid and antigen.  Most importantly, the effect is not obtained in athymic 
mice. Therefore, it seems likely that the enhancing effect of IgD on the immune 
response is T  cell  mediated.  This  interpretation  is also in agreement  with the 
present  observations  that  suggest  a  greater  enhancement  of TD  than  of TI 
responses  in  IgD-producing,  plasmacytoma-bearing  mice.  Although  primary 
responses to TI antigens are also enhanced by TEPC-1017, this effect is not seen 
with TEPC-1033. Both tumors enhance the secondary response to the TI antigen 
TNP-BA,  but  this  may  reflect  an  effect  on  the  priming  for  the  secondary 
response, which is known to be a  T-dependent aspect of the immune response 
even to TI antigens (25). 
There  is  abundant  evidence  (11-14)  for the  existence  of isotype-specific T 110  ENHANCEMENT  OF  ANTIBODY PRODUCTION  BY  IgD 
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FIGURE 4.  Effect of pretreatment with IgD-containing ascites fluid or with Igb isolated from 
such ascites on the primary 19S anti-TNP-KLH  PFC response of BALB/c mice. The mice 
were injected with 1 ml IgD-containing peritoneal exudate  (PE) fluid or saline ("None") on 
days -8. -7, -6, and -5 and received antigen on day 0. PFC per spleen were determined on day 
+5. The 7S response in this experiment was low and did  not differ significantly between 
groups, n = 5, 4, 5, and 5; 100% value was 4,400 PFC/spleen. 
cells,  including  T  cells with Fc receptors for t, a, %  and #  both in humans and 
in  mice.  The  evidence  that  such  cells  can  function  as  suppressor  cells  in  the 
synthesis of some isotypes is quite convincing. To explain the present results we 
postulate  the  existence  of regulatory  T  cells  that  have  Fc  receptors  for  the  6 
chain and that can therefore, in principle, interact with any IgD-bearing B cell, 
although actually the interaction  might be limited to those B  cells whose mem- 
brane immunoglobulin  is cross-linked by antigen.  These hypothetical  t~-specific 
T  cells  might  be suppressors  or  helpers and  our results  on  the  effect of high 
levels of serum IgD can be explained either by "blindfolding" of suppressors or 
by  stimulation  of helpers.  Since,  however,  pretreatment  with  IgD-containing 
ascites  had  a  greater  effect  than  did  injection  of ascites  simultaneously  with 
antigen, it seems more likely that the main event is the activation of a  f-specific 
helper T  cell. 
The  actual  mechanism  of action  of such a  6-specific T  helper  cell  might be 
through a decrease in the biosynthesis of IgD itself. In fact, a decrease in surface XUE ET AL.  111 
IgD, but not of sIgM, has been reported to accompany the blast cell transfor- 
mation of  antigen-stimulated B cells (26), and a recent publication (27) underlines 
the fact that a drastic reduction in IgD, but not in IgM synthesis, occurs early 
after the triggering of B cells with mitogen. In a previous study, we have shown 
a  markedly enhanced antibody production in mice treated with anti-IgD from 
birth, in spite of reduced B cell numbers (8). 
We are thus postulating the existence of a 6-specific helper T  cell that acts by 
suppressing IgD synthesis in those B cells which bear aggregated IgD on their 
surface because they are in the process of reacting with antigen. We propose 
that this suppression of IgD synthesis results in the stimulation of B cell differ- 
entiation. The hypothesis implies that any B cell reacting with a TD antigen has, 
in addition to the conventional antigen-specific helper T  cells, another potential 
source of help in the form of 6-specific T  cells. Our results, showing an enhance- 
ment of antibody production in mice bearing IgD-secreting tumors or receiving 
IgD passively, would then be due to the stimulation of such a  6-specific T  cell 
system. 
The similarity between the effects of B. pertussis and of TEPC-1017  ascites 
fluid on the primary response, and the relative lack of a further enhancement 
by TEPC-1017  of the primary and secondary responses to  DNP-OVA and B. 
pertussis, suggests that IgD and B. pertussis may enhance PFC responses through 
similar mechanisms. B.  pertussis  has been shown to  prevent suppressor  T  cell 
activation (28), but may also have additional effects. On the other hand, endo- 
toxin increases immune responses primarily by its effect on B cells. It is, therefore, 
of interest that the effects of endotoxin and TEPC- 1017 were much more clearly 
additive than those of B. pertussis and TEPC-1017.  Further study is needed to 
elucidate this  most  interesting,  and,  for plasmacytomas, paradoxical  effect of 
IgD-secreting plasmacytomas on the humoral immune response. 
Summary 
Immune  responses  to  trinitrophenylated  hemocyanin  (TNP-KLH),  Ficoll 
(TNP-Ficoll), and Brucella  abortus (TNP-BA) were examined in  BALB/c mice 
bearing subcutaneous transplants ofTEPC-1017 and TEPC-1033, the two known 
IgD-secreting BALB/c plasmacytomas. Both primary and secondary 19S and 7S 
splenic plaque-forming cell (PFC) responses in spleen to intravenously injected 
TNP-KLH were enhanced three to fivefold. Primary responses to TNP-Ficoll 
were 1.5-2 times higher than in control mice (particularly the 7S PFC response). 
Primary responses to TNP-BA were enhanced by TECP-1017 but suppressed by 
TEPC-1033,  while secondary responses  to  TNP-BA  were enhanced three  to 
sevenfold by both tumors.  Intraperitoneal injections of ascites fluid from mice 
bearing TEPC-1017 or TEPC-1033, or of IgD isolated from such ascites fluid, 
caused a similar enhancement of the primary response to TNP-KLH, as did the 
tumor itself, particularly when injected -1  wk before antigen injection.  IgD- 
containing  ascites  fluid  had  no  effect  on  the  response  of athymic  (nu/nu) 
BALB/c mice to  TNP-KLH.  These findings suggest the existence of an  IgD- 
responsive immunoregulatory T  cell. 
The IgD-producing plasmacytomas, TEPC-1017  and TEPC-1033,  were provided by Dr. 112  ENHANCEMENT  OF ANTIBODY  PRODUCTION  BY  IgD 
M. Potter through NCI contract No. 1-CB-25584. The expert technical assistance  of Mr. 
M. K. Bell and Mr. P. Tonda is much appreciated. 
Received for publication  18 August 1983. 
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